All In Biotech

Drug Trial Radar · NCT00595231

Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)

A Multi-Center,Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients With Moderate to Severe Generalized Anxiety Disorder

Last checked: Nov 19, 2026Latest source record: Feb 27, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 239 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

239

Actual

Start

Mar 2008

Primary completion

Oct 2008

Study completion Oct 2008

Sponsor

Lead sponsor
Biotie Therapies Inc.Industry
Sponsor type
Industry
Collaborators
Syneos Health
First posted
Jan 16, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multi-Centered Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients with Moderate to Severe Generalized Anxiety Disorder.

Conditions

  • Generalized Anxiety Disorder

Interventions

  • SYN111Drug

    500 mg for 1 week followed by 1000 mg for 7 weeks

  • PlaceboDrug

    0 mg tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - ObservedTime frame: 8 Weeks
  2. Change From Baseline in Hospital Anxiety and Depression Scale (HADS). Summary StatisticsTime frame: 8 Weeks
  3. Change From Baseline in Montgomery-Asberg Depression Scale (MADRS) Summary Statistics.Time frame: 8 Weeks
  4. Change From Baseline in Clinical Global Impression Scale for Severity of Illness: (CGI-S)Time frame: 8 weeks
  5. Change From Baseline Raskin Depression Scale.Time frame: 8 weeks
  6. Change From Baseline in Covi Anxiety Scale (CAS) - Index Total Score: Summary Statistics ObservedTime frame: 8 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Carmen Research

    Atlanta, Georgia

  • Midwest Clinical Research Center

    Dayton, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.